• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于控制和预防 COVID-19 的中药方剂“呼吸解毒方”的活性成分及作用机制:网络分子对接-LC-MS 分析。

Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MS analysis.

机构信息

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

J Integr Med. 2020 May;18(3):229-241. doi: 10.1016/j.joim.2020.03.004. Epub 2020 Apr 8.

DOI:10.1016/j.joim.2020.03.004
PMID:32307268
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7195604/
Abstract

OBJECTIVE

Lung-toxin Dispelling Formula No. 1, referred to as Respiratory Detox Shot (RDS), was developed based on a classical prescription of traditional Chinese medicine (TCM) and the theoretical understanding of herbal properties within TCM. Therapeutic benefits of using RDS for both disease control and prevention, in the effort to contain the coronavirus disease 2019 (COVID-19), have been shown. However, the biochemically active constituents of RDS and their mechanisms of action are still unclear. The goal of the present study is to clarify the material foundation and action mechanism of RDS.

METHODS

To conduct an analysis of RDS, an integrative analytical platform was constructed, including target prediction, protein-protein interaction (PPI) network, and cluster analysis; further, the hub genes involved in the disease-related pathways were identified, and the their corresponding compounds were used for in vitro validation of molecular docking predictions. The presence of these validated compounds was also measured in samples of the RDS formula to quantify the abundance of the biochemically active constituents. In our network pharmacological study, a total of 26 bioinformatic programs and databases were used, and six networks, covering the entire Zang-fu viscera, were constructed to comprehensively analyze the intricate connections among the compounds-targets-disease pathways-meridians of RDS.

RESULTS

For all 1071 known chemical constituents of the nine ingredients in RDS, identified from established TCM databases, 157 passed drug-likeness screening and led to 339 predicted targets in the constituent-target network. Forty-two hub genes with core regulatory effects were extracted from the PPI network, and 134 compounds and 29 crucial disease pathways were implicated in the target-constituent-disease network. Twelve disease pathways attributed to the Lung-Large Intestine meridians, with six and five attributed to the Kidney-Urinary Bladder and Stomach-Spleen meridians, respectively. One-hundred and eighteen candidate constituents showed a high binding affinity with SARS-coronavirus-2 3-chymotrypsin-like protease (3CL), as indicated by molecular docking using computational pattern recognition. The in vitro activity of 22 chemical constituents of RDS was validated using the 3CL inhibition assay. Finally, using liquid chromatography mass spectrometry in data-independent analysis mode, the presence of seven out of these 22 constituents was confirmed and validated in an aqueous decoction of RDS, using reference standards in both non-targeted and targeted approaches.

CONCLUSION

RDS acts primarily in the Lung-Large Intestine, Kidney-Urinary Bladder and Stomach-Spleen meridians, with other Zang-fu viscera strategically covered by all nine ingredients. In the context of TCM meridian theory, the multiple components and targets of RDS contribute to RDS's dual effects of health-strengthening and pathogen-eliminating. This results in general therapeutic effects for early COVID-19 control and prevention.

摘要

目的

清肺排毒汤(Respiratory Detox Shot,RDS)是在经典中医方剂基础上,结合中医本草理论开发的。已经证明,RDS 在控制和预防 2019 年冠状病毒病(COVID-19)方面具有治疗作用。然而,RDS 的生化活性成分及其作用机制仍不清楚。本研究的目的是阐明 RDS 的物质基础和作用机制。

方法

为了对 RDS 进行分析,构建了一个综合分析平台,包括靶标预测、蛋白质-蛋白质相互作用(PPI)网络和聚类分析;进一步鉴定了与疾病相关途径相关的关键基因,并对其对应的化合物进行了分子对接预测的体外验证。还测量了 RDS 配方样品中这些验证化合物的存在,以定量生化活性成分的丰度。在我们的网络药理学研究中,总共使用了 26 个生物信息学程序和数据库,并构建了 6 个网络,涵盖了整个脏腑,以全面分析 RDS 中化合物-靶标-疾病途径-经络之间的复杂联系。

结果

从已建立的中医数据库中确定了 RDS 中 9 种成分的 1071 种已知化学成分,其中 157 种通过药物相似性筛选,导致成分-靶标网络中有 339 个预测靶标。从 PPI 网络中提取了 42 个具有核心调节作用的关键基因,并在靶标-成分-疾病网络中涉及 134 种化合物和 29 个关键疾病途径。与肺-大肠经络相关的 12 个疾病途径,其中 6 个和 5 个与肾-膀胱和胃-脾经络相关。分子对接使用计算模式识别表明,128 种候选成分与 SARS-CoV-2 3-胰凝乳蛋白酶样蛋白酶(3CL)具有高结合亲和力。使用 3CL 抑制测定法验证了 RDS 的 22 种化学成分的体外活性。最后,使用液相色谱-质谱在数据非靶向分析模式下,通过非靶向和靶向方法使用参考标准,在 RDS 的水性煎剂中证实并验证了这 22 种成分中的 7 种。

结论

RDS 主要作用于肺-大肠、肾-膀胱和胃-脾经络,其他脏腑也由 9 种成分共同覆盖。在中医经络理论中,RDS 的多种成分和靶标有助于 RDS 的强身健体和消除病原体的双重作用。这导致了对 COVID-19 早期控制和预防的一般治疗效果。

相似文献

1
Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MS analysis.用于控制和预防 COVID-19 的中药方剂“呼吸解毒方”的活性成分及作用机制:网络分子对接-LC-MS 分析。
J Integr Med. 2020 May;18(3):229-241. doi: 10.1016/j.joim.2020.03.004. Epub 2020 Apr 8.
2
In silico analysis of the potential mechanism of a preventive Chinese medicine formula on coronavirus disease 2019.基于计算机分析的预防性中药方剂防治 2019 冠状病毒病的潜在作用机制
J Ethnopharmacol. 2021 Jul 15;275:114098. doi: 10.1016/j.jep.2021.114098. Epub 2021 Apr 5.
3
Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.网络药理学与实验验证揭示麻杏石甘汤防治 2019 年冠状病毒病(COVID-19)的潜在作用。
J Ethnopharmacol. 2021 May 10;271:113854. doi: 10.1016/j.jep.2021.113854. Epub 2021 Jan 26.
4
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
5
Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.鉴定 SARS-CoV-2 主蛋白酶的高亲和力抑制剂:迈向有效的 COVID-19 治疗。
Virus Res. 2020 Oct 15;288:198102. doi: 10.1016/j.virusres.2020.198102. Epub 2020 Jul 24.
6
Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.基于与病毒蛋白酶分子相互作用的抗 SARS-CoV 药物的设计与评估。
Molecules. 2020 Aug 27;25(17):3920. doi: 10.3390/molecules25173920.
7
Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.基于网络药理学和分子对接的方法研究化湿败毒方治疗 COVID-19 的分子作用靶点及机制。
Drug Dev Ind Pharm. 2020 Aug;46(8):1345-1353. doi: 10.1080/03639045.2020.1788070. Epub 2020 Jul 8.
8
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.
9
Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.SARS-CoV-2 3CLpro 的结构稳定性和通过实验筛选鉴定槲皮素为抑制剂。
Int J Biol Macromol. 2020 Dec 1;164:1693-1703. doi: 10.1016/j.ijbiomac.2020.07.235. Epub 2020 Aug 1.
10
[Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].基于临床经验和分子对接快速建立中医药防治新型冠状病毒肺炎方案
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1213-1218. doi: 10.19540/j.cnki.cjcmm.20200206.501.

引用本文的文献

1
Role of innate immunity in SARS-CoV-2 infection.固有免疫在2019冠状病毒病感染中的作用。
Biosaf Health. 2023 Sep 9;5(5):280-288. doi: 10.1016/j.bsheal.2023.08.005. eCollection 2023 Oct.
2
Systematic proteome-wide Mendelian randomization to prioritize causal plasma proteins for skin cancers.全蛋白质组范围的系统孟德尔随机化研究,以确定皮肤癌的因果性血浆蛋白优先级。
Commun Biol. 2024 Dec 19;7(1):1681. doi: 10.1038/s42003-024-07403-y.
3
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.重新利用临床可用药物和疗法针对致病靶点来对抗新型冠状病毒。

本文引用的文献

1
[Management of COVID-19: the Zhejiang experience].[新型冠状病毒肺炎的管理:浙江经验]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(2):147-157. doi: 10.3785/j.issn.1008-9292.2020.02.02.
2
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.通过计算方法分析严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的治疗靶点并发现潜在药物
Acta Pharm Sin B. 2020 May;10(5):766-788. doi: 10.1016/j.apsb.2020.02.008. Epub 2020 Feb 27.
3
Can we contain the COVID-19 outbreak with the same measures as for SARS?
MedComm (2020). 2023 May 14;4(3):e254. doi: 10.1002/mco2.254. eCollection 2023 Jun.
4
A Brief Review on Medicinal Plants-At-Arms against COVID-19.药用植物对抗新冠病毒的简要综述
Interdiscip Perspect Infect Dis. 2023 Apr 24;2023:7598307. doi: 10.1155/2023/7598307. eCollection 2023.
5
Application of network pharmacology in the study of the mechanism of action of traditional chinese medicine in the treatment of COVID-19.网络药理学在中药治疗新型冠状病毒肺炎作用机制研究中的应用
Front Pharmacol. 2022 Aug 4;13:926901. doi: 10.3389/fphar.2022.926901. eCollection 2022.
6
Anti-colon Cancer Effects of Kimura & Migo Revealed by Network Pharmacology Integrated With Molecular Docking and Metabolomics Studies.网络药理学结合分子对接和代谢组学研究揭示木村和米果的抗结肠癌作用
Front Med (Lausanne). 2022 Jun 30;9:879986. doi: 10.3389/fmed.2022.879986. eCollection 2022.
7
Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1 Signaling Pathway.爱痛安高级及非瑟酮通过抑制AKT/HIF-1信号通路抑制大鼠癌症诱导的骨痛模型中的肿瘤细胞生长。
J Oncol. 2022 Feb 16;2022:1459636. doi: 10.1155/2022/1459636. eCollection 2022.
8
The Potential Bioactive Components of Nine TCM Prescriptions Against COVID-19 in Lung Cancer Were Explored Based on Network Pharmacology and Molecular Docking.基于网络药理学和分子对接探索九种中医方剂对肺癌合并COVID-19的潜在生物活性成分
Front Med (Lausanne). 2022 Jan 20;8:813119. doi: 10.3389/fmed.2021.813119. eCollection 2021.
9
Mass spectrometry applied to diagnosis, prognosis, and therapeutic targets identification for the novel coronavirus SARS-CoV-2: A review.质谱分析在新型冠状病毒 SARS-CoV-2 的诊断、预后和治疗靶点鉴定中的应用:综述。
Anal Chim Acta. 2022 Feb 22;1195:339385. doi: 10.1016/j.aca.2021.339385. Epub 2021 Dec 20.
10
Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources.用于预防和控制新冠疫情的天然产物:可持续生物资源
Front Pharmacol. 2021 Dec 1;12:758159. doi: 10.3389/fphar.2021.758159. eCollection 2021.
我们能否用应对 SARS 的相同措施来控制 COVID-19 疫情?
Lancet Infect Dis. 2020 May;20(5):e102-e107. doi: 10.1016/S1473-3099(20)30129-8. Epub 2020 Mar 5.
4
Taking the right measures to control COVID-19.采取正确措施控制新冠疫情。
Lancet Infect Dis. 2020 May;20(5):523-524. doi: 10.1016/S1473-3099(20)30152-3. Epub 2020 Mar 5.
5
Traditional Chinese medicine for COVID-19 treatment.用于治疗新冠肺炎的中药。
Pharmacol Res. 2020 May;155:104743. doi: 10.1016/j.phrs.2020.104743. Epub 2020 Mar 4.
6
A Network-Based Approach to Explore the Mechanisms of Alkaloids in Treating Hypertension and Alleviating Alzheimer's Disease.基于网络的方法探讨生物碱治疗高血压和缓解阿尔茨海默病的机制。
Int J Mol Sci. 2020 Mar 4;21(5):1766. doi: 10.3390/ijms21051766.
7
Coronavirus Disease 2019 outbreak: preparedness and readiness of countries in the Eastern Mediterranean Region.2019 年冠状病毒病疫情:东地中海区域各国的防备和准备情况。
East Mediterr Health J. 2020 Feb 24;26(2):136-137. doi: 10.26719/emhj.23.051.
8
Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2).传统中药是针对2019新型冠状病毒(SARS-CoV-2)进行药物研发的资源。
J Integr Med. 2020 Mar;18(2):87-88. doi: 10.1016/j.joim.2020.02.004. Epub 2020 Feb 19.
9
In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.中草药抗 2019 新型冠状病毒的计算机虚拟筛选
J Integr Med. 2020 Mar;18(2):152-158. doi: 10.1016/j.joim.2020.02.005. Epub 2020 Feb 20.
10
COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern.COVID-19:实时传播科学信息以应对国际关注的突发公共卫生事件。
Biosci Trends. 2020 Mar 16;14(1):1-2. doi: 10.5582/bst.2020.01056. Epub 2020 Feb 25.